After filing one lawsuit to try to block Novo Nordisk's $9 billion effort to trump the takeover, Pfizer has returned to the ...

But once a cancer has been detected, the ability to quickly specify exactly which treatment will work is set to have a transformative impact upon oncology, upon the wider world of medicine, and upon ...

The results of the ALLEGORY trial of Gazyva (obinutuzumab) suggest that the anti-CD20 antibody could have broad utility in ...

Tidmarsh, who was named as director of the Center for Drug Evaluation and Research (CDER) in July, told ABC in an interview ...

Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that are ...

Amazon's latest bid to disrupt the healthcare market in the US will see the introduction later this year of electronic kiosks at One Medical sites that will be able to dispense common medications. The ...

Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possible’. This ...

The healthcare company Syncona Limited has announced its newly established portfolio company is to acquire all outstanding shares of Applied Genetic Technologies Corporation (AGTC), a clinical-stage ...

As President Donald Trump started his state visit to the UK, GSK unveiled a massive $30 billion investment in manufacturing and R&D in the US. The revelation is just the latest in a long list of ...

Click Therapeutics' digital therapeutic (DTx) CT-132 has been approved by the FDA, becoming the first treatment of its type in the US for preventing attacks in people with episodic migraine. The ...

Pfizer has filed a lawsuit against Novo Nordisk and Metsera in an attempt to force through its takeover of the weight-loss drug developer and prevent Novo Nordisk from taking its rival bid forward.

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...